SLC6A3 and Cognitive impairment: SRI-32743 interacts with DAT residues that modulate the binding of Tat with DAT and modulates DA uptake in an allosteric manner, leading to a reduction in inhibition of DA uptake by Tat and attenuation of Tat-induced cognitive deficits [23].